FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine.
about
LeishVet guidelines for the practical management of canine leishmaniosisVector transmission of leishmania abrogates vaccine-induced protective immunityAntigenicity, Immunogenicity and Protective Efficacy of Three Proteins Expressed in the Promastigote and Amastigote Stages of Leishmania infantum against Visceral LeishmaniasisAdaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective responseImmucillins ImmA and ImmH Are Effective and Non-toxic in the Treatment of Experimental Visceral LeishmaniasisSand fly salivary proteins induce strong cellular immunity in a natural reservoir of visceral leishmaniasis with adverse consequences for Leishmania.Cross-Protective Immunity to Leishmania amazonensis is Mediated by CD4+ and CD8+ Epitopes of Leishmania donovani Nucleoside Hydrolase Terminal DomainsLeishmania donovani Nucleoside Hydrolase Terminal Domains in Cross-Protective Immunotherapy Against Leishmania amazonensis Murine InfectionGenetic metabolic complementation establishes a requirement for GDP-fucose in Leishmania.One Health: the global challenge of epidemic and endemic leishmaniasisA Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis.Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.Identification of Leishmania infantum chagasi proteins in urine of patients with visceral leishmaniasis: a promising antigen discovery approach of vaccine candidates.Resistance to visceral leishmaniasis is severely compromised in mice deficient of bradykinin B2-receptors.Evaluation of recombinant Leishmania polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly-transmitted Leishmania major in C57BL/6 miceA Chimera Containing CD4+ and CD8+ T-Cell Epitopes of the Leishmania donovani Nucleoside Hydrolase (NH36) Optimizes Cross-Protection against Leishmania amazonesis Infection.Leishmania donovani Nucleoside Hydrolase (NH36) Domains Induce T-Cell Cytokine Responses in Human Visceral Leishmaniasis.F1 Domain of the Leishmania (Leishmania) donovani Nucleoside Hydrolase Promotes a Th1 Response in Leishmania (Leishmania) infantum Cured Patients and in Asymptomatic Individuals Living in an Endemic Area of Leishmaniasis.DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control.NH36 and F3 Antigen-Primed Dendritic Cells Show Preserved Migrating Capabilities and CCR7 Expression and F3 Is Effective in Immunotherapy of Visceral Leishmaniasis.Translating Observations From Leishmanization Into Non-Living Vaccines: The Potential of Dendritic Cell-Based Vaccination Strategies Against Leishmania.Vaccines for canine leishmaniasis
P2860
Q21198917-7FFE3853-C7E9-431C-815D-CAEE9F234944Q27316727-32D88303-7B3A-4E3E-B66B-F4FF130E8CA4Q27318412-EAE6ED8B-E74B-429C-A4D8-4A2FABEAF53CQ28476049-CF0900E0-0818-4E90-AD66-512712712DD4Q28551736-BEE809A5-6F82-45ED-B03F-D5EFA13552DAQ33450546-CF77BE4D-3182-4965-8A11-C3867A6B9C01Q33579979-9BF02544-EA2C-4859-9FC5-CDCFD45D815AQ33737949-6547FD69-57F3-4EC0-A197-DE2941943913Q33826510-9D9534E7-3D56-495A-91E2-A04AA9517E1AQ35544183-EFEB27DE-118F-4DF3-83DE-565589FCA45DQ35687444-204CE503-57BE-4065-BEBD-02508E44514FQ36028999-A57C844E-6449-48FB-9AE3-344393DDAF2CQ36105743-E56BFC35-CDB8-4EBC-BEB6-BB670418F102Q36444714-68D72A81-177B-4ACB-98C8-13D660D38A09Q36682576-8E99AA43-1AFE-4270-9E63-E966EE92631FQ37660825-5C2950A0-47C2-4752-A210-42E5929D73E4Q37681902-A7B1B14A-C58E-4413-91E0-5C2B182875F8Q38658902-EEA719A3-EBF5-4526-B1BB-B730A7355FE8Q38786910-F9357AB3-693D-4C50-A0D3-2339D2DD78B3Q54968645-5CF5D10C-F289-4F66-B087-8BBAEC105935Q55282136-A55F4F26-F800-4959-9A56-8D656D78F723Q56769198-A88A46FB-CDBA-4B89-8254-9A47E1712668
P2860
FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
FML vaccine against canine vis ...... neration to synthetic vaccine.
@en
FML vaccine against canine vis ...... neration to synthetic vaccine.
@nl
type
label
FML vaccine against canine vis ...... neration to synthetic vaccine.
@en
FML vaccine against canine vis ...... neration to synthetic vaccine.
@nl
prefLabel
FML vaccine against canine vis ...... neration to synthetic vaccine.
@en
FML vaccine against canine vis ...... neration to synthetic vaccine.
@nl
P2093
P2860
P356
P1476
FML vaccine against canine vis ...... neration to synthetic vaccine.
@en
P2093
André de Figueiredo Barbosa
Clarisa B Palatnik-de-Sousa
Dirlei Nico
Gulnara P Borja-Cabrera
Irene Soares
Mauricio M Rodrigues
Robson Ronney Bernardo
Sandra Maria Oliveira
Wania R Santos
P2860
P304
P356
10.1586/14760584.7.6.833
P577
2008-08-01T00:00:00Z